Clinical use of biomarkers in the era of Alzheimer's disease treatments
Clinical use of biomarkers in the era of Alzheimer's disease treatments
About this item
Full title
Author / Creator
Publisher
United States: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
With the advent of treatments that specifically target Alzheimer's disease brain pathology, biomarker tests will become an increasingly important part of the routine clinical evaluation of cognitive impairment and guide clinical decision making. Clinicians must ensure they are using accurate and well‐validated biomarker tests and select the most ap...
Alternative Titles
Full title
Clinical use of biomarkers in the era of Alzheimer's disease treatments
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11775455
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11775455
Other Identifiers
ISSN
1552-5260,1552-5279
E-ISSN
1552-5279
DOI
10.1002/alz.14201
